422 related articles for article (PubMed ID: 23018163)
1. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
[TBL] [Abstract][Full Text] [Related]
2. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Andersson KE; de Groat WC; McVary KT; Lue TF; Maggi M; Roehrborn CG; Wyndaele JJ; Melby T; Viktrup L
Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
[TBL] [Abstract][Full Text] [Related]
4. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M
Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.
Morelli A; Sarchielli E; Comeglio P; Filippi S; Mancina R; Gacci M; Vignozzi L; Carini M; Vannelli GB; Maggi M
J Sex Med; 2011 Oct; 8(10):2746-60. PubMed ID: 21812935
[TBL] [Abstract][Full Text] [Related]
9. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053
[TBL] [Abstract][Full Text] [Related]
10. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Zhang WH; Zhang XH
Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
[TBL] [Abstract][Full Text] [Related]
11. Tadalafil for the treatment of benign prostatic hyperplasia.
Mónica FZ; De Nucci G
Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
[TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update].
He PB; Zha PJ; Xu DP
Zhonghua Nan Ke Xue; 2014 Jul; 20(7):651-6. PubMed ID: 25095624
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
14. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.
Yoshinaga R; Kawai Y; Oka M; Fuchikami C; Oyama T
Eur J Pharmacol; 2015 May; 754():92-7. PubMed ID: 25697472
[TBL] [Abstract][Full Text] [Related]
16. [Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Giuliano F; Rouprêt M; Doridot G; de la Taille A
Prog Urol; 2013 Apr; 23(5):283-95. PubMed ID: 23545003
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia.
Giannitsas K; Mitropoulos D; Konstantinopoulos A; Athanasopoulos A; Perimenis P
Expert Opin Pharmacother; 2008 Jul; 9(10):1687-93. PubMed ID: 18570602
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck.
Angulo J; Cuevas P; Fernández A; La Fuente JM; Allona A; Moncada I; Sáenz de Tejada I
J Sex Med; 2012 Sep; 9(9):2293-306. PubMed ID: 22759598
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
[TBL] [Abstract][Full Text] [Related]
20. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
